samedan logo

 
 
spacer
home > pmps > winter 2021 > pandemic poses cold chain challenges
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Pandemic Poses Cold Chain Challenges

As the world watched, the first approved COVID-19 vaccines were transported to the UK to start the mass immunisation process.

The global attention not only highlighted how the pharmaceutical manufacturing and supply chain sectors were working together to rapidly respond in the fight against the virus, it also focused on the cold chain challenges associated with the deployment and safe transportation of COVID-19 vaccines.

These challenges will continue to evolve as various vaccines, with varying temperature requirements for storage and shipment, are approved and transported worldwide.

Cold chain protection, throughout this distribution process, is essential. This can be packaging, or buildings and vehicles, but most crucial is a process to establish an unbroken cold chain. Colder temperatures are more difficult to maintain, as they may require more exotic coolants, such as dry ice, to achieve -80°C.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.


spacer
Adam Tetz is the Director of Worldwide Marketing at Peli BioThermal, and has more than 25 years of marketing experience. He is responsible for telling the story of Peli BioThermal to our worldwide audiences. His areas of responsibility include brand identity, product launch, and communication strategy. Prior to Peli BioThermal, Adam held positions in product management and marketing communication across a variety of industries, including medical software, financial software, information services, and professional consulting services. He holds an MBA in Marketing from the University of Saint Thomas, US, a BA in Advertising from the University of Minnesota, US, and is a veteran of the United States Coast Guard.
spacer
Adam Tetz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta announces license agreement with POINT Biopharma Inc.

Cambridge and Wetherby, UK, 07 January 2021: Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc. (“POINT”), to provide access to Avacta’s pre|CISION technology for the development of tumour-activated radiopharmaceuticals.
More info >>

White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement